Tyrosine kinase inhibitors in systemic sclerosis: The case for imatinib

Current Rheumatology Reports

Volumn 11, Issue 3, 2009, Pages 161-163

  Castelino, Flavia V ^b   Bhattacharyya, Swati ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CYCLOPHOSPHAMIDE; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RELAXIN;

ANEMIA; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; LUNG FIBROSIS; MUSCLE CRAMP; NONHUMAN; NOTE; SIDE EFFECT; SYSTEMIC SCLEROSIS;

EID: 70449674666     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0032-2     Document Type: Note

References (8)

1. C.E. Daniels M.C. Wilkes M. Edens, et al. 2004 Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 114 1308 1316 15520863 1:CAS:528:DC%2BD2cXpsFCgtrg%3D
2. Bhattacharyya S, Ishida W, Wu M, et al.: Smad-independent transforming growth factor-beta signaling in fibroblasts via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009 (in press).
3. J.H. Distler A. Jüngel L.C. Huber, et al. 2007 Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 311 322 17195235 10.1002/art.22314 1:CAS:528:DC%2BD2sXhsFaisL4%3D (Pubitemid 46106205)
4. P.L. Van Daele W.A. Dik H.B. Thio, et al. 2008 Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58 2549 2552 18668570 10.1002/art.23648
5. P.P. Sfikakis V.G. Gorgoulis C.G. Katsiari, et al. 2008 Imatinib for the treatment of refractory, diffuse systemic sclerosis Rheumatology 47 735 737 18326532 10.1093/rheumatology/ken104 1:CAS:528:DC%2BD1cXkvFymtbc%3D (Pubitemid 351619226)
6. Chung L, Fiorentino DF, Benbarak MJ, et al.: Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009 (in press).
7. B.J. Druker F. Guilhot S.G. O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 17151364 10.1056/NEJMoa062867 1:CAS:528:DC%2BD28Xht12ntrzM (Pubitemid 44903745)
8. R. Kerkelä L. Grazette R. Yacobi, et al. 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 908 916 16862153 10.1038/nm1446 (Pubitemid 44175142)